InflaRx N.V.
Clinical-stage biopharmaceutical firm developing C5a/C5aR pathway inhibitors.
IFRX | US
Overview
Corporate Details
- ISIN(s):
- NL0012661870
- LEI:
- Country:
- United States of America
- Address:
- WINZERLAER STR. 2, 7745 JENA
- Website:
- https://www.inflarx.de/
Description
InflaRx N.V. is a clinical-stage biopharmaceutical company that develops anti-inflammatory therapeutics. The company focuses on applying its proprietary technology to discover and develop inhibitors of the complement activation factor C5a and its receptor, C5aR. This approach targets the C5a/C5aR signaling pathway to treat life-threatening and debilitating inflammatory diseases with high unmet medical needs. Its lead product, vilobelimab (GOHIBIC), has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration for the treatment of critically ill, hospitalized adult COVID-19 patients under specific conditions. InflaRx's pipeline aims to develop first-in-class agents for various inflammatory conditions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all InflaRx N.V. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for InflaRx N.V.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for InflaRx N.V. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
